This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Intellia’s CRISPR-based therapy maintained reductions in the levels of a misfold...
Researchers have devised another way to insert large genes into precise spots in...
Plus, news about Applied Therapeutics and Acadia: ❤️ Ionis’ Phase 3 data for...
23andMe has found a buyer. Regeneron will buy the struggling 23andMe through...
CellCentric has raised a $120 million Series C round to support a potential acce...
Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in ...
After more than a month of waiting and negotiations with US regulators, Novavax ...
Happy Saturday and welcome back to Endpoints Weekly! We had a flurry of news thi...
Sarepta Therapeutics is meeting with the FDA in June to discuss expanding the us...
The government “did not act contrary to the law” by requiring drugmakers to seek...
The FDA is prepping to renegotiate its multibillion-dollar, quinquennial user fe...
The FDA on Friday raised efficacy, safety and trial design issues surrounding th...
The US Supreme Court should decline to review a generic drug labeling fight betw...
NEW ORLEANS — The annual American Society of Gene and Cell Therapy meeting felt ...
The Trump administration is partnering with Mark Cuban’s compounding business an...